[go: up one dir, main page]

KR880006206A - 퀴나졸리논 유도체 및 이의 제조방법 - Google Patents

퀴나졸리논 유도체 및 이의 제조방법 Download PDF

Info

Publication number
KR880006206A
KR880006206A KR870012999A KR870012999A KR880006206A KR 880006206 A KR880006206 A KR 880006206A KR 870012999 A KR870012999 A KR 870012999A KR 870012999 A KR870012999 A KR 870012999A KR 880006206 A KR880006206 A KR 880006206A
Authority
KR
South Korea
Prior art keywords
salt
formula
compound
halogen atom
preparation methods
Prior art date
Application number
KR870012999A
Other languages
English (en)
Inventor
요시히사 야마다
유죠 마쯔오까
Original Assignee
아다찌 게이지로
다나베 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다찌 게이지로, 다나베 세이야꾸 가부시끼가이샤 filed Critical 아다찌 게이지로
Publication of KR880006206A publication Critical patent/KR880006206A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

퀴나졸리논 유도체 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(I)의 퀴나졸리논 유도체 또는 이의 염.
    상기식에서, R1은 수소원자 또는 할로겐원자이다.
  2. 제1항에 있어서, 6-클로로-1,2,3,4-테트라하이드로퀴나졸린-4-스피로-4´-이미다졸리딘-2,2´,5´-트리온인 화합물 또는 이의 염.
  3. 제1항에 있어서, 1,2,3,4-테트라하이드로퀴나졸린-4-스피로-4´-이미다졸리딘-2,2´,5´-트리온인 화합물 또는 이의염.
  4. 하기 일반식(Ⅱ)의 화합물을 암모니아 또는 암모니아 공여체와 반응시키고, 임의로 생성물을 이의 염으로 전환시킴을 특징으로 하여, 하기 일반식(I)의 퀴나졸리논 유도체 또는 이의 염을 제조하는 방법.
    상기식에서, R1은 수소원자 또는 할로겐원자이고 R2는 저급알킬이다.
  5. 하기 구조식(I-b)의 화합물 또는 이의 염을 할로겐화제와 반응시키고, 임의로 생성물을 이의 염으로 전환시킴을 특징으로 하여, 하기 일반식(I-a)의 퀴나졸리논 유도체 또는 이의 염을 제조하는 방법.
    상기식에서, R˝은 할로겐원자이다.
  6. 치료학적 유효량의 제1항에 따른 화합물 및 이의 약제학적으로 허용되는 담체로 이루어진 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870012999A 1986-11-21 1987-11-19 퀴나졸리논 유도체 및 이의 제조방법 KR880006206A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61279421A JPS63132889A (ja) 1986-11-21 1986-11-21 キナゾリノン誘導体
JP61-279421 1986-11-21

Publications (1)

Publication Number Publication Date
KR880006206A true KR880006206A (ko) 1988-07-22

Family

ID=17610847

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870012999A KR880006206A (ko) 1986-11-21 1987-11-19 퀴나졸리논 유도체 및 이의 제조방법

Country Status (9)

Country Link
US (1) US4855298A (ko)
EP (1) EP0269378B1 (ko)
JP (1) JPS63132889A (ko)
KR (1) KR880006206A (ko)
AT (1) ATE60334T1 (ko)
CA (1) CA1290756C (ko)
DE (1) DE3767672D1 (ko)
ES (1) ES2031913T3 (ko)
GR (1) GR3001362T3 (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
US5081241A (en) * 1990-10-11 1992-01-14 American Home Products Corporation Spiro-pyridazines and analogs thereof useful as aldose reductase inhibitors
TW202450B (ko) * 1991-06-26 1993-03-21 Dainippon Pharmaceutical Co
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
DK1563788T3 (da) 1995-08-29 2015-05-11 Nitto Denko Corp Mikroperforering af human hud til stofindgift og overvågningsformål
EP0925088A2 (en) 1996-06-28 1999-06-30 Sontra Medical, L.P. Ultrasound enhancement of transdermal transport
US8287483B2 (en) * 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US20040171980A1 (en) * 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
EP3061492B1 (en) * 2002-03-11 2018-09-19 Nitto Denko Corporation Transdermal drug delivery patch system
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US8116860B2 (en) 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US20060094945A1 (en) * 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
US8812071B2 (en) 2007-03-07 2014-08-19 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
DK2152358T3 (da) 2007-04-27 2011-06-27 Echo Therapeutics Inc Hudgennemtrængningsindretning til analytmåling og transdermal medicinafgivelse
US20110288389A9 (en) 2009-03-02 2011-11-24 Seventh Sense Biosystems, Inc. Oxygen sensor
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US20100256524A1 (en) 2009-03-02 2010-10-07 Seventh Sense Biosystems, Inc. Techniques and devices associated with blood sampling
US8827971B2 (en) 2011-04-29 2014-09-09 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US20110105952A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Relatively small devices applied to the skin, modular systems, and methods of use thereof
US20120016308A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
JP6055773B2 (ja) 2010-11-09 2016-12-27 セブンス センス バイオシステムズ，インコーポレーテッド 血液サンプリングのためのシステムおよびインターフェース
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
EP3235429B1 (en) 2011-04-29 2023-06-07 YourBio Health, Inc. Devices and methods for collection of blood from a subject
EP3106092A3 (en) 2011-04-29 2017-03-08 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT321911B (de) * 1971-05-27 1975-04-25 Sandoz Ag Verfahren zur herstellung vonneuen 1-alkyl-4-phenyl-bzw.-4-(2-thienyl)6,7-methylendioxy-34-dihydro-2(1h)-chinazolinonen
JPS53653A (en) * 1976-06-23 1978-01-06 Matsushita Refrig Co Air conditioner
US4282229A (en) * 1977-02-11 1981-08-04 Pfizer Inc. Hydantoin derivatives as therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4273775A (en) * 1979-06-13 1981-06-16 Pfizer Inc. Hydantoin derivatives, anti-diabetic compositions thereof, and method of use thereof
IE50332B1 (en) * 1979-11-13 1986-04-02 Ici Ltd 1'-substituted-spiro(imidazolidine-4,3'-indoline)-2,2',5-triones,processes for their manufacture and pharmaceutical compositions thereof
JPS56104876A (en) * 1980-01-24 1981-08-20 Takeda Chem Ind Ltd Thiazolidine derivative
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
AU566869B2 (en) * 1982-05-11 1987-11-05 Imperial Chemical Industries Plc Spiro (imidazolidine-4,3'-indoline) 2,2',5-triones
US4464380A (en) * 1983-05-25 1984-08-07 Pfizer Inc. Imidazolidinedione derivatives
US4533667A (en) * 1983-05-25 1985-08-06 Pfizer Inc. Imidazolidinedione derivatives
US4617392A (en) * 1983-09-29 1986-10-14 Ortho Pharmaceutical Corporation 4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents
JPH0660152B2 (ja) * 1985-02-09 1994-08-10 日本臓器製薬株式会社 新規オキサルル酸誘導体及び該化合物を含有する血糖低下剤
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications

Also Published As

Publication number Publication date
EP0269378A1 (en) 1988-06-01
JPH0476994B2 (ko) 1992-12-07
ATE60334T1 (de) 1991-02-15
JPS63132889A (ja) 1988-06-04
US4855298A (en) 1989-08-08
DE3767672D1 (de) 1991-02-28
CA1290756C (en) 1991-10-15
GR3001362T3 (en) 1992-09-11
ES2031913T3 (es) 1993-01-01
EP0269378B1 (en) 1991-01-23

Similar Documents

Publication Publication Date Title
KR880006206A (ko) 퀴나졸리논 유도체 및 이의 제조방법
KR850000033A (ko) 8-클로로-1,5-벤조티아제핀 유도체의 제조방법
KR840007412A (ko) 벤조-헤테로 고리 화합물의 제조방법
KR880012526A (ko) l-페닐-3-나프탈레닐옥시프로판아민
KR870010078A (ko) 신규의 아미노산 유도체 및 그의 제조방법
KR880007514A (ko) 키놀린 화합물
KR890005141A (ko) 안드로스타-1,4-디엔-3,17-디온의 메틸렌 유도체의 제조방법
KR890007738A (ko) 파킨슨씨병 치료용 에르골린 유도체
NZ208691A (en) Dihydrodibenzocycloheptylidene-ethylpiperazine derivatives and pharmaceutical compositions thereof
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR890011904A (ko) 안드로스타-1,4, -디엔-3,17-디온의 6-메틸렌 유도체 합성방법
KR890000482A (ko) (8β)-1-알킬-6-(치환된) 에르 골린의 시클로알킬아미드
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR880701234A (ko) 신규 비페닐 유도체와 그의 제조 방법 및 용도
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
KR920007995A (ko) 벤즈아미드 유도체
KR830004320A (ko) 퀴나졸린 유도체의 제조방법
KR830006302A (ko) 신규 피리미딘 유도체의 제조방법
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR840001160A (ko) 벤조디옥산-이미다졸린 유도체의 제조방법
KR890002013A (ko) 치환된 피리딜알킬 케톤의 제조방법
KR890002011A (ko) 5-할로 게노-6-아미노-니코틴산 할라이드. 이의 제조방법 및 용도
KR920005720A (ko) 피리딘 유도체 그 제조방법 및 그 약학적 조성물
KR920002594A (ko) 5-이소티아졸아민 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19871119

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19930511

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19930729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19930511

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I